Page last updated: 2024-08-23

pirfenidone and Fatty Liver

pirfenidone has been researched along with Fatty Liver in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Chang, S; Deng, W; Li, S; Li, Y; Yang, S; Zhang, R	1
Armendáriz-Borunda, J; Escutia-Gutiérrez, R; García-Bañuelos, J; Monraz-Méndez, CA; Rodríguez-Sanabria, JS; Sandoval-Rodríguez, A; Santos-García, A	1
Alvarez-Álvarez, A; Arellano-Olivera, I; Armendáriz-Borunda, J; Flores-Contreras, L; Lucano-Landeros, S; Mena-Enriquez, MG; Sanchez-Parada, MG; Sandoval-Rodríguez, AS	1

Trials

1 trial(s) available for pirfenidone and Fatty Liver

Article	Year
Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC gastroenterology, 2014, Jul-27, Volume: 14 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Cytokines; Fatty Liver; Female; Gene Expression; Hepatitis C, Chronic; Humans; Interleukin-6; Liver; Liver Cirrhosis; Male; Middle Aged; Pyridones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha	2014

Article

Year

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.

BMC gastroenterology, 2014, Jul-27, Volume: 14

Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Cytokines; Fatty Liver; Female; Gene Expression; Hepatitis C, Chronic; Humans; Interleukin-6; Liver; Liver Cirrhosis; Male; Middle Aged; Pyridones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta1; Treatment Outcome; Tumor Necrosis Factor-alpha

2014

Other Studies

2 other study(ies) available for pirfenidone and Fatty Liver

Article	Year
Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023, Volume: 72, Issue:9 Topics: Animals; Diet, High-Fat; Fatty Liver; Lipids; Liver; Mice; Mice, Inbred C57BL; STAT3 Transcription Factor	2023
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Scientific reports, 2021, 06-03, Volume: 11, Issue:1 Topics: Animals; Biomarkers; Collagen Type I; Cytokines; Disease Models, Animal; Disease Susceptibility; Fatty Liver; Gene Expression Regulation; Immunohistochemistry; Inflammation Mediators; Lipid Metabolism; Liver Function Tests; Male; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Pyridones	2021

Article

Year

Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023, Volume: 72, Issue:9

Topics: Animals; Diet, High-Fat; Fatty Liver; Lipids; Liver; Mice; Mice, Inbred C57BL; STAT3 Transcription Factor

2023

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Scientific reports, 2021, 06-03, Volume: 11, Issue:1

Topics: Animals; Biomarkers; Collagen Type I; Cytokines; Disease Models, Animal; Disease Susceptibility; Fatty Liver; Gene Expression Regulation; Immunohistochemistry; Inflammation Mediators; Lipid Metabolism; Liver Function Tests; Male; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Pyridones

2021